As part of JPMorgan’s JPM plan to stop offering service for the direct investment trust and ISA customers, nearly £1.5 billion of its direct customer accounts are set to be acquired by online stockbrokers, Hargreaves Lansdown and The Share Centre.
In sync with this move, The Share Centre is expected to take on nearly 20,000 of JPMorgan’s investment trust clients, holding around £750 million in assets from JPMorgan Asset Management.
Richard Stone, the chief executive officer at The Share Centre stated, “It is a privilege to have been chosen by the company as the best home for their investment trust customers and we look forward to helping these customers work towards their investment goals.”
Then again, Hargreaves is set to take on as many as 33,000 retail fund clients, holding £765 million in assets, mainly in open-ended funds.
While JPMorgan has currently given customers the privilege to transfer holdings to Hargreaves free of cost, they are also allowed to select any other service provider apart from Hargreaves, if they wish to.
This will be the second transfer of JPMorgan ISA fund clients to Hargreaves.
Patrick Thomson, the CEO of Europe, Middle East and Africa for JPMorgan Asset Management said, “After due consideration and having worked closely with Hargreaves Lansdown in the past, we concluded they would be best placed to provide a high quality service to clients holding our managed funds as we cease the administration of ISA accounts.”
In the past few years, Hargreaves has taken on some investment trust clients from BlackRock BLK, Legg Mason LM and a few other asset managers.
Notably, amid efforts to focus on own funds, JPMorgan already said in 2015 that it would no longer offer FTSE shares and other non-JPMorgan investments to direct clients. The company planned to shut JPMorgan Sipp and ISA, and decided to offer only its range of OEICs and investment trusts to individual clients.
JPMorgan’s efforts to expand into new markets by opening branches, its focus on strengthening the credit card business and improving loan balances are expected to continue to support revenues. However, dismal mortgage banking performance (owing to lower origination volume and refinancing activities) remains a major concern for the company. Moreover, its significant dependence on capital market revenues makes us wary.
So far this year, JPMorgan’s shares have gained 7.9%, underperforming the industry’s growth of 11.5%.
Currently, JPMorgan carries a Zacks Rank #4 (Sell).
A better-ranked stock from the same space is Fifth Third Bancorp FITB. Its earnings estimates for the current year have been revised by 1.1% over the past 60 days. Its shares have gained 13.6% year to date. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fifth Third Bancorp (FITB) : Free Stock Analysis Report
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
BlackRock, Inc. (BLK) : Free Stock Analysis Report
Legg Mason, Inc. (LM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research